N 2 (199) 2026. P. 92–97

PLEIOTROPIC EFFECTS OF STATINS IN HEPATOLOGY AND VENOUS THROMBOEMBOLISM: REAL-WORLD EVIDENCE ANALYSIS (2016–2025)

M. M. Perepeliuk

Odesa National Medical University, Odesa, Ukraine

DOI 10.32782/2226-2008-2026-2-13

Background. Statins, as inhibitors of HMG-CoA reductase, exert pleiotropic effects beyond lipid lowering, including endothelial-protective, anti-inflammatory, and antifibrotic properties relevant to liver diseases and venous thromboembolism (VTE).

Objective. To summarize real-world evidence on the pleiotropic effects of statins in hepatology, define the “therapeutic window” in cirrhosis, and evaluate their role in VTE prevention.

Materials and Methods. A structured literature search was performed in PubMed for the period 2016–2025 using predefined keywords related to statins, cirrhosis, hepatocellular carcinoma, portal hypertension, and VTE. A total of 261 publications were identified, of which 35 met the inclusion criteria. To minimize bias, studies employing modern pharmacoepidemiological approaches were prioritized, including propensity score matching, time-lag analysis, and sensitivity analyses.

Results. Statin therapy is associated with improved intrahepatic hemodynamics through KLF2 signaling and nitric oxide pathways, as well as antifibrotic effects mediated by Rho-kinase inhibition. In real-world cohort studies, statin use has been linked to reduced risks of cirrhosis decompensation, hepatocellular carcinoma, and mortality, particularly in patients with compensated disease. The concept of a “therapeutic window” suggests the most favorable benefit-risk balance in patients with Child–Pugh class A cirrhosis. In the context of VTE, statins demonstrate modest effects in primary prevention but a more consistent reduction in recurrence risk. Observational data support a favorable safety profile and challenge the concept of “statin phobia.”

Conclusions. Statins may be considered as adjunctive therapy in selected patients with chronic liver disease and increased thrombotic risk. The greatest benefit appears to be observed in compensated stages of disease, while further randomized controlled trials are needed to establish causality and refine clinical indications.

Keywords: statins; pleiotropic effects; liver cirrhosis; venous thromboembolism; real-world evidence.

REFERENCES

  1. Abdulrazzak E, Fakhoury B, Jaan A, et al. Statin therapy and portal pressure reduction in cirrhosis: a systematic review and meta-analysis. Liver Int. 2025;45(10):e70326. https://doi.org/10.1111/liv.70326.
  2. Simon TG, Duberg AS, Aleman S, et al. Lipophilic statins and risk for hepatocellular carcinoma and death in patients with chronic viral hepatitis: results from a nationwide Swedish population. Ann Intern Med. 2019;171(5):318–327. https://doi.org/10.7326/M18-2753.
  3. Kunutsor SK, Seidu S, Khunti K. Statins and primary prevention of venous thromboembolism: a systematic review and meta-analysis. Lancet Haematol. 2017;4(2):e83–e93. https://doi.org/10.1016/S2352-3026(16)30184-3.
  4. Karim ME, Gustafson P, Petkau J, Tremlett H. Comparison of statistical approaches for dealing with immortal time bias in drug effectiveness studies. Am J Epidemiol. 2016;184(4):325–335. https://doi.org/10.1093/aje/kwv445.
  5. Suissa S, Dell’Aniello S. Time-related biases in pharmacoepidemiology. Pharmacoepidemiol Drug Saf. 2020;29(9):1101–1110. https://doi.org/10.1002/pds.5083.
  6. Mahmud N, Chapin S, Goldberg DS, Reddy KR, Taddei TH, Kaplan DE. Statin exposure is associated with reduced development of acute-on-chronic liver failure in a Veterans Affairs cohort. J Hepatol. 2022;76(5):1100–1108. https://doi.org/10.1016/j.jhep.2021.12.034.
  7. Li R, Yuan M, Yu S, et al. Effect of statins on the risk of recurrent venous thromboembolism: a systematic review and meta-analysis. Pharmacol Res. 2021;165:105413. https://doi.org/10.1016/j.phrs.2020.105413.
  8. Bosch J, Gracia-Sancho J, Abraldes JG. Cirrhosis as a new indication for statins. Gut. 2020;69(5):953–962. https://doi.org/10.1136/gutjnl-2019-318237.
  9. Alvarado-Tapias E, Brujats A, Puente A, et al. Hemodynamic effects of carvedilol plus simvastatin in cirrhosis with severe portal hypertension and suboptimal response to β-blockers: a double-blind, placebo-controlled, randomized trial. Hepatology. 2025;82(1):140–154. https://doi.org/10.1097/HEP.0000000000001148.
  10. Gratacós-Ginès J, Pose E. Role of statins in cirrhosis and portal hypertension. Clin Liver Dis (Hoboken). 2023;22(2):50–57. https://doi.org/10.1097/CLD.0000000000000015.
  11. Rodríguez S, Raurell I, Torres-Arauz M, García-Lezana T, Genescà J, Martell M. A nitric oxide-donating statin decreases portal pressure with a better toxicity profile than conventional statins in cirrhotic rats. Sci Rep. 2017;7:40461. https://doi.org/10.1038/srep40461.
  12. Lastuvkova H, Alaei Faradonbeh F, Schreiberova J, et al. Atorvastatin modulates bile acid homeostasis in mice with diet-induced nonalcoholic steatohepatitis. Int J Mol Sci. 2021;22(12):6468. https://doi.org/10.3390/ijms22126468.
  13. Zhang X, Lou D, Fu R, Wu F, Zheng D, Ma X. Association between statins types with incidence of liver cancer: an updated meta-analysis. Curr Med Chem. 2024;31(6):762–775. https://doi.org/10.2174/0929867330666230701000400.
  14. Li X, Sheng L, Liu L, Hu Y, Chen Y, Lou L. Statin and the risk of hepatocellular carcinoma in patients with hepatitis B virus or hepatitis C virus infection: a meta-analysis. BMC Gastroenterol. 2020;20(1):98. https://doi.org/10.1186/ s12876-020-01222-1.
  15. Tarar ZI, Farooq U, Inayat F, et al. Statins decrease the risk of hepatocellular carcinoma in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis. World J Exp Med. 2024;14(4):98543. https://doi.org/10.5493/ wjem.v14.i4.98543.
  16. Caro L, Prueksaritanont T, Fandozzi CM, et al. Evaluation of pharmacokinetic drug interactions of the direct-acting antiviral agents elbasvir and grazoprevir with pitavastatin, rosuvastatin, pravastatin, and atorvastatin in healthy adults. Clin Drug Investig. 2021;41(2):133–147. https://doi.org/10.1007/s40261-020-00974-8.
  17. Balasubramanian R, Maideen NMP. HMG-CoA reductase inhibitors (statins) and their drug interactions involving CYP enzymes, P-glycoprotein and OATP transporters: an overview. Curr Drug Metab. 2021;22(5):328–341. https://doi.org/10.2 174/1389200222666210114122729.
  18. Chang FM, Wang YP, Lang HC, et al. Statins decrease the risk of decompensation in hepatitis B virus- and hepatitis C virus-related cirrhosis: a population-based study. Hepatology. 2017;66(3):896–907. https://doi.org/10.1002/hep.29172.
  19. Sharma R, Simon TG, Hagström H, et al. Statins are associated with a decreased risk of severe liver disease in individuals with noncirrhotic chronic liver disease. Clin Gastroenterol Hepatol. 2024;22(4):749–759.e19. https://doi.org/10.1016/ j.cgh.2023.04.017.
  20. Marrache MK, Rockey DC. Statins for treatment of chronic liver disease. Curr Opin Gastroenterol. 2021;37(3):200–207. https://doi.org/10.1097/MOG.0000000000000716.
  21. Pose E, Napoleone L, Amin A, et al. Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Gastroenterol Hepatol. 2020;5(1):31–41. https://doi.org/10.1016/S2468-1253(19)30320-6.
  22. Amjad W, Jiang Z, Lai M. Statin use in cirrhosis and its association with incidence of portal vein thrombosis. J Gastroenterol Hepatol. 2024;39(5):955–963. https://doi.org/10.1111/jgh.16495.
  23. Ogura S, Yoshida Y, Kurahashi T, et al. Targeting the mevalonate pathway is a novel therapeutic approach to inhibit oncogenic FoxM1 transcription factor in human hepatocellular carcinoma. Oncotarget. 2018;9:21022–21035. https://doi.org/10.18632/ oncotarget.24781.
  24. Wang Y, Wang W, Wang M, Shi J, Jia X, Dang S. A meta-analysis of statin use and risk of hepatocellular carcinoma. Can J Gastroenterol Hepatol. 2022;2022:5389044. https://doi.org/10.1155/2022/5389044.
  25. Ruan J, Fang Y, Zhang X, Zhang Q, Song J. Statins exposure and adverse events in participants with chronic viral hepatitis: a meta-analysis based on cohort studies. npj Gut and Liver. 2025;2(1):7. https://doi.org/10.1038/s44355-025-00020-4.
  26. Cheung KS, Yeung YWM, Wong WS, Li B, Seto WK, Leung WK. Statins associate with lower risk of biliary tract cancers: a systematic review and meta-analysis. Cancer Med. 2023;12(1):557–568. https://doi.org/10.1002/cam4.4942.
  27. Mach F, Baigent C, Catapano AL, et al. Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. Eur Heart J. 2018;39(27):2526–2539. https://doi.org/10.1093/eurheartj/ehy182.
  28. Kim HS, Lee SH, Kim H, et al. Statin-related aminotransferase elevation according to baseline aminotransferases level in real practice in Korea. J Clin Pharm Ther. 2016;41(3):266–272. https://doi.org/10.1111/jcpt.12377.
  29. Zhou XD, Kim SU, Yip TCF, et al. Long-term liver-related outcomes and liver stiffness progression of statin usage in steatotic liver disease. Gut. 2024;73(11):1883–1892. https://doi.org/10.1136/gutjnl-2024-333074.
  30. Sung S, Al-Karaghouli M, Kalainy S, Cabrera Garcia L, Abraldes JG. A systematic review on pharmacokinetics, cardiovascular outcomes and safety profiles of statins in cirrhosis. BMC Gastroenterol. 2021;21:120. https://doi.org/10.1186/ s12876-021-01704-w.
  31. Newman CB, Preiss D, Tobert JA, et al. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2019;39(2):e38–e81. https://doi.org/10.1161/ ATV.0000000000000073.
  32. Rao AK, Del Carpio-Cano F, Janapati S, et al. Effects of simvastatin on tissue factor pathway of blood coagulation in STATCOPE (simvastatin in the prevention of COPD exacerbations) trial. J Thromb Haemost. 2021;19(7):1709–1717. https://doi.org/10.1111/jth.15282.
  33. Barale C, Frascaroli C, Senkeev R, Cavalot F, Russo I. Simvastatin effects on inflammation and platelet activation markers in hypercholesterolemia. Biomed Res Int. 2018;2018:6508709. https://doi.org/10.1155/2018/6508709.
  34. Skajaa N, Szépligeti SK, Horváth-Puhó E, Ghanima W, Hansen JB, Sørensen HT. Initiation of statins and risk of venous thromboembolism: population-based matched cohort study. Thromb Res. 2019;184:99–104. https://doi.org/10.1016/j.thromres.2019.11.003.
  35. Stewart LK, Sarmiento EJ, Kline JA. Statin use is associated with reduced risk of recurrence in patients with venous thromboembolism. Am J Med. 2020;133(8):930–935.e8. https://doi.org/10.1016/j.amjmed.2019.12.032.
View article PDF